Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 4/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.44 |
| ▸ | CDK2 | P24941 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23982233 | 0.83 | CDK1 (0.60) | CDK1ADORA2AADORA2BADORA1CCNB1 | |
| SCHEMBL19553504 | 0.78 | ADORA2A (0.52) | CDK1ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL5160241 | 0.78 | ADORA2A (0.56) | CDK1ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL12417532 | 0.77 | CDK1 (0.60) | CDK1ADORA2AADORA2BADORA1CCNB1 | |
| SCHEMBL5160396 | 0.77 | ADORA2A (0.57) | CDK1ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL15756748 | 0.76 | ADORA2A (0.52) | CDK1ADORA2AADORA2BADORA1 | |
| SCHEMBL22349417 | 0.76 | ADORA2A (0.57) | CDK1ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL129642 | 0.75 | CDK1 (0.68) | CDK1ADORA2AADORA1CCNB1CCNE1 | |
| SCHEMBL15756525 | 0.75 | CDK1 (0.50) | CDK1ADORA2AADORA2BADORA1CCNE1 | |
| SCHEMBL11370037 | 0.75 | ADORA2A (0.56) | ADORA2AADORA2BADORA1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048203-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048203-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | HPRT1, APRT, NUDT1 | CDK1 3035/4885ADORA2A 33/4885ADORA2B 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.